title: Suitability and perspectives on using recombinant insect cells for the production of virus-like particles.
abstract: Virus-like particles (VLPs) can be produced in recombinant protein production systems by expressing viral surface proteins that spontaneously assemble into particulate structures similar to authentic viral or subviral particles. VLPs serve as excellent platforms for the development of safe and effective vaccines and diagnostic antigens. Among various recombinant protein production systems, the baculovirus-insect cell system has been used extensively for the production of a wide variety of VLPs. This system is already employed for the manufacture of a licensed human papillomavirus-like particle vaccine. However, the baculovirus-insect cell system has several inherent limitations including contamination of VLPs with progeny baculovirus particles. Stably transformed insect cells have emerged as attractive alternatives to the baculovirus-insect cell system. Different types of VLPs, with or without an envelope and composed of either single or multiple structural proteins, have been produced in stably transformed insect cells. VLPs produced by stably transformed insect cells have successfully elicited immune responses in vivo. In some cases, the yield of VLPs attained with recombinant insect cells was comparable to, or higher than, that obtained by baculovirus-infected insect cells. Recombinant insect cells offer a promising approach to the development and production of VLPs.
authors.affiliation: Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501, Japan, yamaji@kobe-u.ac.jp.
authors.forename: Hideki
authors.initials: H
authors.lastname: Yamaji
mesh_terms: D000818:Animals; D016367:Baculoviridae / Q000235:genetics / Q000254:growth & development*; D001709:Biotechnology / Q000379:methods*; D018929:Cell Culture Techniques / Q000379:methods; D002460:Cell Line; D005822:Genetic Vectors; D006801:Humans; D007313:Insecta; D013678:Technology, Pharmaceutical / Q000379:methods*; D022701:Virosomes / Q000302:isolation & purification* / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D022701:Virosomes